Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4A10 in Relapsed or Refractory ALL or LL
NCT07586618Phase 1Recruiting
- Sponsor
- Allterum Therapeutics
- Start
- Jun 2026
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 4A10 in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Allterum Therapeutics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 1 year and Recommended Phase 2 Dose at 1 year. Started Jun 2026; status: recruiting.
02
Drugs
4A10
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT07586618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07586618.